Evidence map›Paper›PMID 41266527›Full record

ArticleCommunications biology2025

Extracellular vesicles modulate integrin signaling and subcellular energetics to promote pulmonary lymphangioleiomyomatosis metastasis.

Anil Kumar Kalvala, Ashok Silwal, Bhaumik Patel, Apoorva Kasetti, Kirti Rajendra Shetty, Jan Markiewski, Jun-Hung Cho, Gerard Lara, Elizabeth Daugherity, Rémi Diesler and 6 more

Abstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Anil Kumar Kalvala *Department of Immunotherapeutics & Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, USA.ORCID http://orcid.org/0000-0003-4500-1472
Ashok Silwal *Department of Immunotherapeutics & Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, USA.
Bhaumik PatelDepartment of Immunotherapeutics & Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, USA.
Apoorva KasettiDepartment of Immunotherapeutics & Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, USA.
Kirti Rajendra ShettyDepartment of Immunotherapeutics & Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, USA.
Jan MarkiewskiDepartment of Immunotherapeutics & Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, USA.ORCID http://orcid.org/0009-0005-3898-4097
Jun-Hung ChoDepartment of Immunotherapeutics & Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, USA.
Gerard LaraDepartment of Immunotherapeutics & Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, USA.
Elizabeth DaugherityDepartment of Immunotherapeutics & Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, USA.ORCID http://orcid.org/0000-0003-2403-7070
Rémi DieslerDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Venkatesh PooladandaVincent Center for Reproductive Biology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, USA.
Bo R RuedaVincent Center for Reproductive Biology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9489-8699
Elizabeth Petri HenskeDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7978-6699
Jane J YuDepartment of Internal Medicine, University of Division of Pulmonary, Critical Care and Sleep Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Maciej MarkiewskiDepartment of Immunotherapeutics & Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, USA. maciej.markiewski@ttuhsc.edu.ORCID http://orcid.org/0000-0002-8271-8918
Magdalena KarbowniczekDepartment of Immunotherapeutics & Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, USA. magdalena.karbowniczek@ttuhsc.edu.ORCID http://orcid.org/0000-0001-8062-6844

Funding

Investigate the role of extracellular vesicles in promoting the progression of pulmonary lymphangioleiomyomatosisR01HL160972 · NHLBI · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI KARBOWNICZEK, MAGDALENA, YU, JANE · 2022 to 2025
$2.8M
Cellular determinants of responsiveness to mTOR inhibitors in LAMR01HL172914 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI YAN XU, Jane Yu · 2025 to 2026
$1.4M
Dysregulation of sphingolipid metabolism and signaling in LAMR01HL178848 · NHLBI · UNIVERSITY OF FLORIDA · PI Jane Yu · 2025 to 2026
$1.4M
NHLBI NIH HHS R01 HL160972NHLBI NIH HHS R01 HL172914NHLBI NIH HHS R01 HL178848U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL160972
6 · The paper itself

Abstract

Pulmonary lymphangioleiomyomatosis (LAM) is a metastatic sarcoma, but the mechanisms of LAM metastasis are unknown. Extracellular vesicles (EVs) regulate cancer metastasis; however, their roles in LAM have not yet been thoroughly investigated. Here, we report the discovery of distinct LAM-EV subtypes derived from primary tumor or metastasizing LAM cells that promote LAM metastasis through ITGα6/β1-c-Src-FAK signaling, triggered by the shuttling of ATP synthesis to cell pseudopodia or the activation of integrin adhesion complex, respectively. This signaling leads to increased LAM cell migration, invasiveness, and stemness and regulates metastable (hybrid) phenotypes that are all pivotal for metastasis. Mouse models corroborate in vitro data by demonstrating a significant increase in lung metastatic burden upon exposure to EVs through distinct mechanisms involving either lung resident fibroblasts or metalloproteinases' activation that are EV subtype dependent. The clinical relevance of these findings is underscored by increased EV biogenesis in LAM patients and the enrichment of these EV cargo with lung-tropic integrins and metalloproteinases. These findings establish EVs as a novel therapeutic target in LAM, warranting future clinical studies.

Indexed as

Energy MetabolismExtracellular VesiclesIntegrinsLung NeoplasmsLymphangioleiomyomatosisSignal TransductionAnimalsCell Line, TumorCell MovementFemaleHumansMiceNeoplasm MetastasisIntegrins

Identifiers

PMID41266527
PMCPMC12634698

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.